Survey finds high prevalence of HTLV-1 infection among teens and adults in Gabon

NewsGuard 100/100 Score

Researchers find that the retrovirus is highly endemic and widely distributed across Gabon

A study published in PLOS Neglected Tropical Diseases, by Mirdad Kazanji, of the Centre International de Recherches Medicales de Franceville in Gabon, and the Institut Pasteur de la Guyane in French Guiana, suggests that 30 years after the first epidemiological survey of the seroprevalence of Human T-cell lymphotropic virus type 1 (HTLV-1) infections in Gabon, the country remains highly endemic, with a seroprevalence of 7.3%.

“HTLV-1 Virus”. Credit: CDC, Wikimedia Commons, 2007

HTLV-1 infections affect approximately 5 to 10 million people globally and can cause adult T-cell lymphoma, myelopathy, and a variety of other diseases. Thirty years ago, researchers conducted an epidemiological study in Gabon, revealing an HTLV-1 infection prevalence of 5%-10.5%. To evaluate current disease distribution, the authors collected blood samples, medical histories, and sociodemographic data from 4,381 participants, aged 15-90 years old, living across all 9 provinces of Gabon over a three-year period. Of the 4,381 people tested, 320 were positive for HTLV-1, contributing to 7.3% prevalence country-wide. Additionally, the authors measured for geographic distribution, behavioral and sociodemographic risk factors that may contribute to disease transmission.

Importantly, the study did not include children under the age of 15, so further epidemiological research is required to gain a better understanding of transmission and prevalence rate in child populations. According to the authors, the results indicate that, “preventive measures to decrease spread and transmission of this human retrovirus are urgently warranted.” Among their recommendations are nationwide sexual health programming, systematic HTLV-1 screening of potential blood donors, and screening and educational outreach among pregnant women to decrease risk of mother-child transmission.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel immune cell therapy may be a promising strategy for combating HBV infection